Evidence map›Paper›PMID 36270085›Full record

ArticleThe International journal on drug policy2022

U.S. state policies on opioid prescribing during the peak of the prescription opioid crisis: Associations with opioid overdose mortality.

Michele J Buonora, David B Hanna, Chenshu Zhang, Marcus A Bachhuber, Lorlette H Moir, Pooja S Salvi, Chinazo O Cunningham, Joanna L Starrels

Abstract read
In one paragraph

Article in The International journal on drug policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Pain Research and Treatment: Policy Implications.Policy insights from the behavioral and brain sciences · 2024
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michele J BuonoraDivision of General Internal Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA; National Clinician Scholars Program, Yale University School of Medicine, New Haven, CT, USA; Departments of Medicine, Veterans Affairs Connecticut Healthcare System & Yale University School of Medicine, West Haven, CT, USA. Electronic address: michele.buonora@yale.edu.
David B HannaDepartment of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Chenshu ZhangDivision of General Internal Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.
Marcus A BachhuberDivision of General Internal Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA; Department of Medicine, Section of Community and Population Medicine, Louisiana State University Health Sciences Center-New Orleans School of Medicine, New Orleans, LA, USA.
Lorlette H MoirDivision of General Internal Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA; Infectious Disease Prevention, Investigation & Care Services Section, Bureau of Infectious Disease Control, Division of Public Health Services, New Hampshire Department of Health & Human Services, NH, USA.
Pooja S SalviDivision of General Internal Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.
Chinazo O CunninghamDivision of General Internal Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.
Joanna L StarrelsDivision of General Internal Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.

Funding

Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HARRIS GOLDSTEIN · 2017 to 2026
$28.3M
Mentoring Junior Investigators to Tackle the Opioid EpidemicK24DA046309 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI STARRELS, JOANNA L. · 2018 to 2023
$876k
Prediction of heart failure in HIV-infected individualsK01HL137557 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HANNA, DAVID B. · 2017 to 2020
$711k
NHLBI NIH HHS K01 HL137557NIAID NIH HHS P30 AI124414NIDA NIH HHS K24 DA046309
6 · The paper itself

Abstract

backgroundIn response to the opioid overdose crisis in the United States, many states implemented policies to guide opioid prescribing, but their impact on overdose mortality (prescription and non-prescription) remains poorly understood. We examined the impact of U.S. state opioid-prescribing policies on opioid overdose mortality following implementation.

methodsWe calculated opioid overdose mortality rates from 1999-2016 by U.S. state using the CDC WONDER database, overall and separately for overdose deaths from prescription and non-prescription opioids. For each state, policies active on 1/1/2014 were reviewed for the presence and strength of six provisions recommending judicious opioid prescribing practices; "strong" provisions used the words "should," "shall," or "must". Interrupted time series (ITS) tested the association of each strong provision with overdose mortality, overall and separately for prescription and non-prescription opioids, in the two years following implementation. Sensitivity analyses compared between states, used time-lagged analyses, and excluded synthetic opioids from non-prescription opioid deaths.

resultsAll six provisions had consistent direction of effect in ITS and sensitivity analyses. Strong provisions for prescriber training and limits on opioid dose reduced the slope of overall and prescription opioid overdose mortality in both ITS and sensitivity analyses. Reduced non-prescription opioid overdose mortality was only associated with strong provision for prescriber training. Some provisions had a negative impact. In ITS, strong provision for prescriber response to misuse increased the slope of non-prescription opioid overdose mortality. Strong provision for mandatory prescription drug monitoring program use had no relationship with overdose mortality in ITS and was associated with increased overall, prescription and non-prescription opioid overdose mortality in between-state sensitivity analysis.

conclusionOpioid prescribing policies in U.S. states at the peak of the prescription opioid epidemic had modest mortality benefit, and did not reduce non-prescription opioid overdose mortality. A strong provision for prescriber training was the only provision associated with reduced prescription and non-prescription opioid overdose mortality. These findings can inform future efforts addressing prescription drug epidemics.

Indexed as

Drug OverdoseOpiate OverdoseAnalgesics, OpioidHumansOpioid EpidemicPractice Patterns, Physicians'United StatesAnalgesics, OpioidOpioidsOverdose mortalityUS state policies

Identifiers

PMID36270085
PMCPMC9742344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.